Effect of immunoglobulin therapy on the rate of infections in multiple myeloma patients undergoing autologous stem cell transplantation or treated with immunomodulatory agents

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 2, Issue 1, 2010, Pages

  Khalafallah, Alhossain ^a,b   Maiwald, Matthias ^c   Cox, Amanda ^a,d   Burns, Denise ^a,b   Bates, Gerald ^a,b   Hannan, Terry ^a   Seaton, David ^a   Fernandopulle, Bernadene ^a   Meagher, Damien ^e   Brain, Terry ^a  

^a LAUNCESTON GENERAL HOSPITAL   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

^c KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e Mersey Hospital   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; DEXAMETHASONE; FAMCICLOVIR; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; LENALIDOMIDE; STEROID; SULFAMETHOXAZOLE; THALIDOMIDE; TRIMETHOPRIM;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HERPES ZOSTER; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION PREVENTION; INFECTION RISK; LOWER RESPIRATORY TRACT INFECTION; MALE; MULTIPLE MYELOMA; PNEUMOCYSTIS PNEUMONIA; RECURRENT INFECTION; RISK REDUCTION; SEX RATIO; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION;

EID: 79952779689     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/MJHID.2010.005     Document Type: Article

References (24)

1. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003; 78:21-33.
2. Savage DG, Lindenbaum J, Garrett TJ. Biphasic pattern of bacterial infection in multiple myeloma. Ann Intern Med. 1982; 96:47-50.
3. Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol. 2007; 138:563-79.
4. Twomey J. Infections complicating multiple myeloma and chronic lymphocytic leukaemia. Arch Intern Med 1973; 32:562-5.
5. Weaver CH, Schwartzberg LS, Hainsworth J, Greco FA, Li W, Buckner CD, West WH. Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers. Bone Marrow Transplant. 1997; 19:671-8.
6. Offidani M, Corvatta L, Olivieri A, Mele A, Brunori M, Montanari M, Rupoli S, Scalari P, Leoni P. A predictive model of varicella-zoster virus infection after autologous peripheral blood progenitor cell transplantation. Clin Infect Dis. 2001; 32:1414-22.
7. Cesana C, Nosari AM, Klersy C, Miqueleiz S, Rossi V, Ferrando P, Valentini M, Barbarano L, Morra E. Risk factors for the development of bacterial infections in multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules. Haematologica. 2003; 88:1022-8.
8. Hargreaves RM, Lea JR, Griffiths H, Faux JA, Holt JM, Reid C, Bunch C, Lee M, Chapel HM. Immunological factors and risk of infection in plateau phase myeloma. Journal of Clinical Pathology. 1995; 48:260-6.
9. Chanan-Khan A, Sonneveld P, Schuster M, Stadtmauer E, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Neuwirth R, Anderson KC, Richardson PG. Analysis of herpes zoster evens among Bortezomib treated patients in the phase III APEX study. J Clin Oncol. 2008; 26:4784-90.
10. Yoshida M. Compromised immune function in multiple myeloma. Nippon Rinsho. 2007; 65:2238-42 (abstr).
11. Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. Lancet. 1994; 343:1059-63.
12. Chapel HM, Lee M. The use of intravenous immune globulin in multiple myeloma. Clin Exp Immunol. 1994; 97:21-4.
13. Busse PJ, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol. 2002; 109:1001-4.
14. McKenna RW, Kyle RA, Kuehl WM, Grogan TM, Harris NL, Cpupland RW. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (editors): 3rd Ed., IARC Press, Lyon, 2008; 200-13.
15. Corral LG, Kaplan G. Immunomudulation by thalidomide and thalidomide analogues. Ann Rheum Dis. 1999; 58:107-13.
16. Barlogie B, Tricot G, Anaissie E. Thalidomide in the management of multiple myeloma. Semin Oncol. 2001; 28:577-82.
17. Anderson KC. Lenalidomide and thalidomide: mechanisms of action - similarities and differences. Semin Haematol. 2005;42:S3-8.
18. Ocio EM, Mateos MV, Maiso P, Pandiella A, San-Miguel JF. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol. 2008; 9:1157-65.
19. Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D, Williams SF, Bensinger W, Badros AZ, Vescio R, Kenvin L, Yu Z, Olesnyckyj M, Zeldis J, Knight R, Anderson KC. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood. 2009; 114:772-8. Epub 2009.
20. Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, Todryk S, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB, Dalgleish AG. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother. 2009; 58:1033-45.
21. Galustian C, Dalgleish A. Lenalidomide: a novel anticancer drug with multiple modalities. Expert Opin Pharmacother. 2009; 10:125-33.
22. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foà R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD; Multiple Myeloma (010) Study Investigators Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007; 357:2123-32.
23. Richardson PG, Hideshima T, Anderson KC. Bortezomib (PS-341): A novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control. 2003;10:361-9.
24. Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and metaanalysis. Leuk Lymphoma. 2009;50:764-72.